Sunesis plots $15.5M offering to support trial

Sunesis Pharmaceuticals is offering 44.1 million units, each consisting of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a public offering price of $0.35 per unit. The company anticipates it will raise $15.5 million from the offiering, which is expected to close on October 6. The company plans to use the funding to support a Phase III clinical trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia, and for working capital and general corporate purposes.

- here's Sunesis' release on the offering

ALSO: Nasdaq has granted Sunesis a six-month extension for regaining compliance with the market's $1 per share minimum price rule. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.